ContraFect Corporation

DB:22R Stock Report

Market Cap: €2.2m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

ContraFect Management

Management criteria checks 2/4

ContraFect's CEO is Roger Pomerantz, appointed in Apr 2019, has a tenure of 4.08 years. total yearly compensation is $2.23M, comprised of 31.5% salary and 68.5% bonuses, including company stock and options. directly owns 0% of the company’s shares, worth €1.30. The average tenure of the management team and the board of directors is 4.1 years and 9.1 years respectively.

Key information

Roger Pomerantz

Chief executive officer

US$2.2m

Total compensation

CEO salary percentage31.5%
CEO tenure4.1yrs
CEO ownership0.00006%
Management average tenure4.1yrs
Board average tenure9.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Roger Pomerantz's remuneration changed compared to ContraFect's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2022US$2mUS$702k

-US$65m

Sep 30 2022n/an/a

-US$60m

Jun 30 2022n/an/a

-US$48m

Mar 31 2022n/an/a

-US$35m

Dec 31 2021US$2mUS$666k

-US$20m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$26m

Dec 31 2020US$4mUS$605k

-US$28m

Sep 30 2020n/an/a

-US$32m

Jun 30 2020n/an/a

-US$41m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$2mUS$413k

-US$13m

Sep 30 2019n/an/a

US$3m

Jun 30 2019n/an/a

US$4m

Mar 31 2019n/an/a

-US$7m

Dec 31 2018US$90kn/a

-US$38m

Sep 30 2018n/an/a

-US$48m

Jun 30 2018n/an/a

-US$46m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$89kn/a

-US$16m

Sep 30 2017n/an/a

-US$10m

Jun 30 2017n/an/a

-US$19m

Mar 31 2017n/an/a

-US$26m

Dec 31 2016US$97kn/a

-US$29m

Compensation vs Market: Roger's total compensation ($USD2.23M) is above average for companies of similar size in the German market ($USD418.12K).

Compensation vs Earnings: Roger's compensation has increased whilst the company is unprofitable.

CEO

Roger Pomerantz (65 yo)

4.1yrs

Tenure

US$2,225,482

Compensation

Dr. Roger James Pomerantz, M.D., F.A.C.P., serves as Director at X-Vax Technology, Inc. He serves as an Independent Vice Chairman of the Board of Enlivex Therapeutics Ltd. since May 2022. He is Independent...

Leadership Team

NamePositionTenureCompensationOwnership
Roger Pomerantz
Chairman4.1yrsUS$2.23m0.000060%
€ 1.3
Michael Messinger
Chief Financial Officer4.5yrsUS$957.21k0.0015%
€ 31.8
Natalie Bogdanos
General Counsel8.8yrsUS$844.90k0.000060%
€ 1.3
Matthew Salamone
Vice President of Human Resources1.2yrsno datano data
Gary Woodnutt
Senior Vice President of Translational Sciences & Preclinical Development1.9yrsno datano data

4.1yrs

Average Tenure

59yo

Average Age

Experienced Management: 22R's management team is considered experienced (4.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Roger Pomerantz
Chairman9.1yrsUS$2.23m0.000060%
€ 1.3
Sol Barer
Lead Independent Director12.1yrsUS$176.04k0.065%
€ 1.4k
Steven Gilman
Vice Chairman8yrsUS$160.54k0.0017%
€ 35.9
Lishan Aklog
Independent Director2.9yrsUS$150.54k0%
€ 0
Michael Otto
Independent Director9.1yrsUS$160.04k0.00064%
€ 13.9
Leon Smith
Member of Scientific Advisory Boardno datano datano data
Peter Palese
Member of Scientific Advisory Boardno datano datano data
Adolfo Garcia-Sastre
Member of Scientific Advisory Boardno datano datano data
Vincent Fischetti
Chairman of Scientific Advisory Boardno datano datano data
Cary Sucoff
Independent Director13yrsUS$155.54k0.0049%
€ 106.5
David Low
Independent Director9.1yrsUS$165.04k0.030%
€ 640.0
Daniel Capon
Member of Scientific Advisory Boardno datano datano data

9.1yrs

Average Tenure

69yo

Average Age

Experienced Board: 22R's board of directors are considered experienced (9.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/05/14 12:49
End of Day Share Price 2023/02/14 00:00
Earnings2022/12/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ContraFect Corporation is covered by 13 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Keay NakaeChardan Capital Markets, LLC
Esther Lannie HongJanney Montgomery Scott LLC